Companies · Other Technology

Cellular Longevity, Inc.

SAN FRANCISCO · Other Technology

Diligence memoA one-page analyst read on Cellular Longevity, Inc. — recommendation, valuation, rhythm, risks.
$137.3M
Total raised · real
6
Rounds
0.3×
Latest step-up
Top 3%
Sector rank · raised
Series C
Latest stage · inferred · Fri Oct 11 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Cellular Longevity, Inc. looks under-valued against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.29× the median modeled value of Series C Other Technology companies in 2022–2024 (187 peers) — value vs value, same stage and era.
Quiet
  • Last raise 21 mo ago; this sector typically re-raises about every 13 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Technology

Cellular Longevity, Inc. is one of 21292 Other Technology companies tracked from SAN FRANCISCO. By capital raised it ranks among the largest (ahead of 98% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
12
Investors (latest)
2024-10-11
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$250M$500M$750M$1.0BSeries A · 2020-01-03 Raised $4.9M (real) Modeled valuation $135M (est)$4.9M$135MSeries A2020Series A · 2020-09-03 Raised $5.4M (real) Modeled valuation $141M (est)$5.4M$141MSeries A2020Series A · 2020-12-17 Raised $832K (real) Modeled valuation $19M (est)$832K$19MSeries A2020Series B · 2021-08-31 Raised $28M (real) Modeled valuation $560M (est)$28M$560MSeries B2021Series C · 2024-03-05 Raised $76M (real) Modeled valuation $786M (est)$76M$786MSeries C2024Series C · 2024-10-11 Raised $22M (real) Modeled valuation $190M (est)$22M$190MSeries C2024+$5.4M+$832K+$28M+$76M+$22MCumulative $137M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$4.9M · 2020
Series A extension$5.4M · 2020
Series A extension$832K · 2020
Series B$27.7M · 2021
Series C$76.3M · 2024
Series C extension$22.2M · 2024

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 60%.

Modeled valuation trajectory
$190.3M
Base estimate est.
$84.0M
Conservative case
$278.2M
Upside case
$147.8M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ca $40M–$100M round). Valuation is modeled from stage benchmarks scaled by the technology sector profile. Directional, not a quoted figure.

Series A · modeled $134.8M · 2020-01-032020Series A · modeled $140.8M · 2020-09-03Series A · modeled $19.1M · 2020-12-17Series B · modeled $559.7M · 2021-08-31Series C · modeled $785.9M · 2024-03-05Series C · modeled $190.3M · 2024-10-112024
Model inputs · modeled:benchmark-stage-stepup-v1
15%
Dilution assumption
Implied ownership sold in the financing.
76%
Survival probability
57% low · 88% high
1.35×/yr
Annual markup
1.55×/yr upside case
1.7 yr
Elapsed time used
1.7 yr actual, capped for stale marks
technology
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
11 mo
Avg between rounds
$28.8M/yr
Capital velocity
6.5 yr
On record since
2020
First round
6
Rounds on file
How it compares to the market

Benchmarked against 21292 companies in Other Technology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 43× above median
This company$137.3M
Sector median$3.2M
Latest round — vs other Series C rounds in sector (real $, this stage) 0.4× of median
This company$22.2M
Sector median$50.0M
Modeled value — vs sector median (estimate, all stages) 5.1× above median
This company$190.3M
Sector median$37.3M

Raised more than 98% of sector peers (real $). Modeled value above 83% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series C) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #161 of 187.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0M$1.0BCapital raised (log)LinkSquares, Inc. · Series C Raised $160.2M · modeled $1.9B (est)Semperis Ltd. · Series C Raised $130.0M · modeled $1.8B (est)Veev Group, Inc. · Series C Raised $94.5M · modeled $1.8B (est)GPI Acquisitions, Inc. · Series C Raised $175.0M · modeled $1.7B (est)DVX Ventures LLC · Series C Raised $119.8M · modeled $1.5B (est)Ncr Corp · Series C Raised $73.7M · modeled $1.5B (est)RelationalAI, Inc. · Series C Raised $74.0M · modeled $1.4B (est)Nantero Inc · Series C Raised $172.9M · modeled $1.4B (est)MoEngage, Inc. · Series C Raised $172.2M · modeled $1.4B (est)H2scan Corp · Series C Raised $83.2M · modeled $1.4B (est)ITsavvy Holdings, LLC · Series C Raised $81.4M · modeled $1.4B (est)Coherent Group Inc. · Series C Raised $74.0M · modeled $1.3B (est)Cellular Longevity, Inc. (this company) Raised $137.3M · modeled $190.3M (est)Cellular Longevity, Inc.
CompanyStageRaised · realValue · estvs peer med.
LinkSquares, Inc.Series C$160.2M$1.9B2.80×
Semperis Ltd.Series C$130.0M$1.8B2.74×
Veev Group, Inc.Series C$94.5M$1.8B2.71×
GPI Acquisitions, Inc.Series C$175.0M$1.7B2.47×
DVX Ventures LLCSeries C$119.8M$1.5B2.27×
Ncr CorpSeries C$73.7M$1.5B2.19×
RelationalAI, Inc.Series C$74.0M$1.4B2.07×
Nantero IncSeries C$172.9M$1.4B2.06×
MoEngage, Inc.Series C$172.2M$1.4B2.05×
H2scan CorpSeries C$83.2M$1.4B2.03×
ITsavvy Holdings, LLCSeries C$81.4M$1.4B2.03×
Coherent Group Inc.Series C$74.0M$1.3B2.02×
Cellular Longevity, Inc. this companySeries C$137.3M$190.3M0.29×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$4.9M2020-01-03$22.1M$134.8M90%
Series A$5.4M2020-09-03$24.8M$140.8M90%
Series A$832K2020-12-17$3.8M$19.1M90%
Series B$27.7M2021-08-31$153.9M$559.7M90%
Series C$76.3M2024-03-05$508.5M$785.9M90%
Series C$22.2M2024-10-11$147.8M$190.3M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$4.9M2020-01-03
    • First recorded raise — entered as Series A.
    • 19 investors on this round.
  2. Series A$5.4M2020-09-03
    • Raised 8 mo later, in step with the ~13 mo sector norm.
    • Round roughly the size of the prior one.
    • 28 investors on this round.
  3. Series A$832K2020-12-17
    • Came back fast: 3 mo vs the ~13 mo sector norm.
    • Round 6.6× smaller than the prior — bridge or down round.
    • 10 investors on this round.
  4. Series B$27.7M2021-08-31
    • Raised 8 mo later, in step with the ~13 mo sector norm.
    • Round 33.3× larger than the prior — scaling up.
    • 42 investors on this round.
  5. Series C$76.3M2024-03-05
    • Raised again after 30 mo — slower than the ~13 mo sector norm.
    • Round 2.8× larger than the prior — scaling up.
    • 38 investors on this round.
  6. Series C$22.2M2024-10-11
    • Came back fast: 7 mo vs the ~13 mo sector norm.
    • Round 3.4× smaller than the prior — bridge or down round.
    • 12 investors on this round.
Intelligence
2025 ~Q3
Modeled next raise · ~11mo cadence
$22.2M
Modeled next size est.range $22.2M$35.5M
0.3×
Last step-up
$28.8M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Kevin Zhang10 other2024-03
Blake Scholl1 other2024-03
Linda Rhodes1 other2024-10
Celine-Lea Halioua-Haubold2020-01
Laura Deming2024-03
Registry & provenance

Cellular Longevity, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1799919
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Justworks, Inc.Other TechnologySeries C$130.4M$198.1Msame sector · same stage
Kustomer, Inc.Other TechnologySeries C$190.0M$203.2Msame sector · same stage
TMGcore, Inc.Other TechnologySeries C$90.0M$199.7Msame sector · same stage
Teamworks Innovations, Inc.Other TechnologySeries C$234.4M$176.3Msame sector · same stage
Achronix Semiconductor CorpOther TechnologySeries C$79.1M$183.5Msame sector · same stage
Fugue, Inc.Other TechnologySeries C$78.6M$195.4Msame sector · same stage
Quanterix CorpOther TechnologySeries C$71.8M$194.1Msame sector · same stage
Gloo Holdings, LLCOther TechnologySeries C$64.6M$184.6Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Life Management Group Of Companies IncOther TechnologySeries A$164.4M85%
LastSeat, Inc.Other TechnologyPre-Seed$8.0M85%
Cell Works Group IncOther TechnologySeries B$471.4M85%
Durable, Inc.Other TechnologySeed$27.4M84%
Lifegait, Inc.Other TechnologySeed$10.5M84%
LivingLab, Inc.Other TechnologySeed$93.4M83%
My Lasting Legacy, Inc.Other TechnologySeries A$182.8M83%
Lifedna, Inc.Other TechnologySeed$69.1M83%
Frequently asked
How much funding has Cellular Longevity, Inc. raised?
Cellular Longevity, Inc. has raised approximately $137.3M in disclosed capital across 6 recorded financing rounds, aggregated from public filings.
What is Cellular Longevity, Inc.'s estimated valuation?
Provath's modeled valuation for Cellular Longevity, Inc. is approximately $190.3M (modeled range $84.0M–$278.2M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Cellular Longevity, Inc. at?
Cellular Longevity, Inc.'s latest modeled financing stage is Series C. Its most recent recorded round closed around Fri Oct 11.
What does Cellular Longevity, Inc. do and where is it based?
Cellular Longevity, Inc. operates in the Other Technology sector, based in SAN FRANCISCO.
Explore related

See where Cellular Longevity, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Cellular Longevity, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.